NEW YORK (TheStreet) -- Pfizer (PFE - Get Report) ticked upward Wednesday after Goldman Sachs tagged a "buy" rating on the stock and set a $35 price target after the pharmaceutical giant dropped its $117 billion takeover bid for AstraZeneca (AZN).
The firm cited a "significant gap" between the current value and fair value of the share price.
"PFE has a significant cash position and [balance sheet] optionality and will likely use it to fill in gaps in growth through M&A," Goldman Sachs wrote in a research note. The firm added Pfizer's leadership "will do what it takes to unlock value, be it a break-up, M&A or whatever drives the most value."
The stock was up 0.34% to $29.71 at 1:58 p.m.